论文部分内容阅读
目的 研究P—糖蛋白 (P - gp)在卵巢组织中的表达及其临床意义。 方法 用免疫组化的方法测定 4 0例卵巢恶性肿瘤及 10例卵巢良性肿瘤组织中的P—糖蛋白表达及其与组织学类型和分级 ,临床分期及术前化疗的关系。结果 P - gp在良性肿瘤中无阳性表达。在恶性肿瘤中P -gp表达阳性率为 3 7 5 0 % ,P - gp表达与组织学类型、临床分期、术前化疗无关。P -gp阳性表达在低分化癌中占 5 8 3 3 % ,高于高、中分化癌 (14 2 8% )。P - gp阳性者缓解期短 ,易近期内复发。结论 免疫组化法测定P - gp表达对评估卵巢恶性肿瘤多药耐药及预后具有一定的临床价值。P -gp阳性者对多药型药物耐药 ,疗效及预后差。
Objective To study the expression of P - glycoprotein (P - gp) in ovarian tissue and its clinical significance. Methods The expression of P-glycoprotein in 40 cases of ovarian cancer and 10 cases of benign ovarian tumor was detected by immunohistochemistry and its relationship with histological type and grade, clinical stage and preoperative chemotherapy. Results There was no positive expression of P - gp in benign tumors. The positive rate of P-gp expression in malignant tumors was 3750%. The expression of P-gp was not related to histological type, clinical stage and preoperative chemotherapy. The positive expression of P-gp accounted for 58.33% in poorly differentiated carcinoma, which was higher than that in high-differentiated carcinoma (14.28%). P - gp positive remission period is short, easy to relapse within the near future. Conclusion The immunohistochemical method to determine the expression of P - gp has some clinical value in the evaluation of multidrug resistance and prognosis of ovarian cancer. P-gp positive multi-drug resistance, poor efficacy and prognosis.